Lumacaftor: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lumacaftor. Educational only — not medical advice.
Labeled uses
ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Source: FDA labeling via NIH DailyMed (set 3fc1c40e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.